ProQR Therapeutics N.V. SEC Filings

ProQR Therapeutics entered an underwriting agreement for an underwritten registered direct offering of 27,624,310 ordinary shares at $1.81 per share. The company expects aggregate net proceeds of about $46.5 million from this offering, after underwriting discounts and expenses.

Concurrently, ProQR agreed to sell 5,100,780 additional shares to Eli Lilly in a private placement at the same price, for approximately $9.2 million. Lilly is subject to a lockup, standstill and receives registration rights, while ProQR plans to use the combined proceeds mainly for research, clinical development and general corporate purposes.

ProQR Therapeutics N.V. is offering 27,624,310 ordinary shares at a public offering price of $1.81 per share. Concurrently, ProQR has a separately negotiated private placement with Eli Lilly and Company for 5,100,780 ordinary shares at the same public offering price; that private placement is not registered as part of this offering but will close simultaneously, and the closing of the offering is not contingent on the private placement. The underwriters expect to deliver the shares on or about June 26, 2026. ProQR reports estimated net proceeds from the offering together with the concurrent private placement of approximately $55.8 million, and states it intends to use proceeds to fund research and clinical development, working capital, capital expenditures and other general corporate purposes. ProQR expects 141,119,032 ordinary shares to be outstanding immediately after this offering and the concurrent private placement.

ProQR Therapeutics reported positive Phase 1 target engagement data for AX-0810, its first Axiomer RNA editing candidate, in healthy volunteers. The multiple ascending dose study enrolled 33 participants, with AX-0810 showing dose-dependent NTCP modulation, including up to 8-fold increases in total bile acids versus a predefined 2-fold target threshold.

Concordant changes in conjugated bile acids, increased TUDCA after oral challenge, and unchanged hormone levels support on-target activity while preserving other NTCP functions. Safety and tolerability were favorable with no serious adverse events and pharmacokinetics showed an approximately eight-week half-life, suggesting sustained target engagement.

These data provide the first clinical validation of ProQR’s Axiomer RNA editing platform and support its NTCP franchise, including next-generation candidate AX-0811. ProQR outlines plans for AX-0811 Phase 1, an investigator-initiated biliary atresia trial, and a potentially registration-enabling Phase 2 program, alongside additional Axiomer-based pipeline candidates.

Van Herk Investments B.V. and affiliated entities report beneficial ownership of 15,384,250 ProQR Therapeutics ordinary shares, representing 14.6% of the class based on 105,362,551 shares outstanding as of March 31, 2026.

The group amended its Schedule 13D to disclose that it will vote against agenda items 7, 8 and 9 at ProQR’s 2026 Annual General Meeting, which concern increasing authorized share capital, broad authority for the board to issue shares and authorization for share repurchases. Van Herk argues these proposals grant overly broad discretion over the capital structure, could cause substantial dilution without further shareholder approval, lack specific transaction justification and lack meaningful safeguards. They have engaged advisors to communicate with other shareholders and are evaluating potential legal proceedings while continuing to hold the shares for investment.

ProQR Therapeutics N.V. director Hinsch Gylvin Lykke received a grant of options to buy 14,495 ordinary shares. These share options have an exercise price of $1.42 per share and expire on June 1, 2036, functioning as equity-based compensation rather than an open-market trade.

According to the vesting terms, 25% of the options vest and become exercisable on June 2, 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments thereafter, contingent on continuous service. After this grant, the filing shows 14,495 derivative securities held.

ProQR Therapeutics N.V. reports the results of its 2026 annual general meeting held on June 2, 2026. Shareholders adopted the 2025 annual accounts and appropriation of net result with 99.7% of votes cast in favor.

They granted discharge from liability to Board members for their 2025 duties with 69.5% support and approved the appointment of Dr. Lykke Hinsch Gylvin as a non-executive Board member with 99.7% support. KPMG Accountants N.V. was appointed external auditor for the 2027 financial year with 99.8% approval.

Shareholders also approved amendments to the Articles of Association to increase authorized capital with 65.4% support, authorized the Board to issue ordinary shares with 64.3% support, and to repurchase ordinary shares with 66.7% support. Following the meeting, the Board confirmed updated Audit, Compensation/Nominating/Corporate Governance, and Research and Development committee compositions.

ProQR Therapeutics N.V. director Hinsch Gylvin Lykke filed an initial Form 3 as an insider of the company. The data provided shows no reported transactions, no derivative positions, and no holding entries, so this filing mainly establishes insider status without disclosing any ownership changes.

ProQR Therapeutics reported first quarter 2026 results showing continued investment in its RNA editing pipeline and a larger loss. Revenue was €2.0 million, down from €4.5 million a year earlier, mainly from its collaboration with Eli Lilly. The company recorded a net loss of €13.4 million, or €0.13 per share, versus €10.1 million, or €0.10 per share, in 2025, driven by R&D of €11.8 million and G&A of €3.9 million.

Cash and cash equivalents were €81.1 million at March 31, 2026, compared with €92.4 million at year-end 2025, with net cash used in operating activities of €11.1 million. Management states this cash provides funding into at least the twelve months following issuance and, in forward-looking commentary, indicates a runway into mid 2027. Operationally, ProQR is advancing its Axiomer RNA editing platform, with lead program AX‑0810 on track for target engagement data in healthy volunteers in the second quarter of 2026 and an investigator-initiated biliary atresia trial in China planned ahead of Phase 2 development.

ProQR Therapeutics reported first quarter 2026 results and provided a pipeline update centered on its Axiomer RNA editing platform. Revenue was €2.0 million, down from €4.5 million a year earlier, and the company recorded a net loss of €13.4 million, or €0.13 per diluted share, versus a €10.1 million loss, or €0.10 per share, in 2025.

Cash and cash equivalents were €81.1 million at March 31, 2026 compared with €92.4 million at year-end 2025, with net cash used in operating activities of €11.1 million, improving from €15.8 million in the prior-year quarter. Lead program AX-0810 remains on track for target engagement data in the second quarter of 2026, and an investigator-initiated biliary atresia trial in China is planned with initial data targeted for the first half of 2027.